414 related articles for article (PubMed ID: 33273236)
1. Transitioning From Immunosuppressants to Dupilumab in Pediatric Atopic Dermatitis.
Ludwig CM; Hsiao JL; Lio PA; Shi VY
Dermatitis; 2021 Oct; 32(1S):S4-S7. PubMed ID: 33273236
[TBL] [Abstract][Full Text] [Related]
2. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
3. The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis.
Kamal MA; Kovalenko P; Kosloski MP; Srinivasan K; Zhang Y; Rajadhyaksha M; Lai CH; Kanamaluru V; Xu C; Sun X; Simpson EL; Paller AS; Siegfried EC; Shumel B; Bansal A; Al-Huniti N; Davis JD
Clin Pharmacol Ther; 2021 Nov; 110(5):1318-1328. PubMed ID: 34270797
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
5. Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data.
Paller AS; Beck LA; Blauvelt A; Siegfried EC; Cork MJ; Wollenberg A; Chen Z; Khokhar FA; Vakil J; Zhang A; Bansal A; Cyr SL
Pediatr Dermatol; 2022 Mar; 39(2):187-196. PubMed ID: 35083774
[TBL] [Abstract][Full Text] [Related]
6. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
Br J Dermatol; 2020 May; 182(5):1120-1135. PubMed ID: 31407311
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS.
Silverberg JI; Yosipovitch G; Simpson EL; Kim BS; Wu JJ; Eckert L; Guillemin I; Chen Z; Ardeleanu M; Bansal A; Kaur M; Rossi AB; Graham NMH; Patel N; Gadkari A
J Am Acad Dermatol; 2020 Jun; 82(6):1328-1336. PubMed ID: 32135208
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal utilization of systemic immunomodulators before and after dupilumab approval in children with atopic dermatitis.
Anand P; Schneeweiss S; Mostaghimi A; Schneeweiss MC
Pediatr Dermatol; 2023 Jan; 40(1):132-134. PubMed ID: 36403606
[TBL] [Abstract][Full Text] [Related]
9. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2).
Thaçi D; L Simpson E; Deleuran M; Kataoka Y; Chen Z; Gadkari A; Eckert L; Akinlade B; Graham NMH; Pirozzi G; Ardeleanu M
J Dermatol Sci; 2019 May; 94(2):266-275. PubMed ID: 31109652
[TBL] [Abstract][Full Text] [Related]
11. Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review.
Igelman S; Kurta AO; Sheikh U; McWilliams A; Armbrecht E; Jackson Cullison SR; Kress DW; Smith A; Castelo-Soccio L; Treat J; Boothe WD; Diaz LZ; Levy ML; Patel A; Lee LW; Fraile-Alonso MC; Antaya RJ; Shah S; Kittler N; Arkin L; Siegfried E
J Am Acad Dermatol; 2020 Feb; 82(2):407-411. PubMed ID: 31606479
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab for the treatment of adolescents with atopic dermatitis.
Senner S; Seegräber M; Frey S; Kendziora B; Eicher L; Wollenberg A
Expert Rev Clin Immunol; 2020 Jul; 16(7):641-650. PubMed ID: 32720530
[TBL] [Abstract][Full Text] [Related]
13. Atopic Dermatitis: A Guide to Transitioning to Janus Kinase Inhibitors.
Rick JW; Lio P; Atluri S; Hsiao JL; Shi VY
Dermatitis; 2023; 34(4):297-300. PubMed ID: 36125529
[TBL] [Abstract][Full Text] [Related]
14. Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy.
Gori N; Chiricozzi A; Malvaso D; D'Urso DF; Caldarola G; De Simone C; Peris K
Dermatology; 2021; 237(4):535-541. PubMed ID: 33477153
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
[TBL] [Abstract][Full Text] [Related]
16. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
17. Management of inadequate response and adverse effects to dupilumab in atopic dermatitis.
Narla S; Silverberg JI; Simpson EL
J Am Acad Dermatol; 2022 Mar; 86(3):628-636. PubMed ID: 34126094
[TBL] [Abstract][Full Text] [Related]
18. Systemic Biologic Management of Atopic Dermatitis.
Dao DD; Flowers RH
Adv Exp Med Biol; 2024; 1447():139-149. PubMed ID: 38724791
[TBL] [Abstract][Full Text] [Related]
19. Can we safely use systemic treatment in atopic dermatitis during the COVID-19 pandemic? Overview of selected conventional and biologic systemic therapies.
Marko M; Pawliczak R
Expert Rev Clin Immunol; 2021 Jun; 17(6):619-627. PubMed ID: 33866905
[No Abstract] [Full Text] [Related]
20. Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Thaçi D; Deleuran M; Blauvelt A; Bissonnette R; de Bruin-Weller M; Hide M; Sher L; Hussain I; Chen Z; Khokhar FA; Beazley B; Ruddy M; Patel N; Graham NMH; Ardeleanu M; Shumel B
Am J Clin Dermatol; 2020 Aug; 21(4):567-577. PubMed ID: 32557382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
